Journal of Medicinal Chemistry · 2022 · 23 citations · 30 references
MedicineCardiologyPharmacologyDrug DesignDrug DiscoveryMolecular PharmacologyCardiac PharmacotherapyCardiovascular PharmacodynamicsCardiovascular PharmacologyCanonical Wnt Beta-catenin PathwayCanonical Wnt PathwayCardiac Fibrosis ModulationCardiac RemodelingCardiovascular Drug PharmacologyFibroblast ActivationNovel Cardiovascular Drug DevelopmentWnt Signaling Activation
Lysine-specific demethylase 5B (KDM5B) has been recognized as a potential drug target for cardiovascular diseases. In this work, we first found that the KDM5B level was increased in mouse hearts after transverse aortic constriction (TAC) and in Ang II-induced activated cardiac fibroblasts. Structure-based design and further optimizations led to the discovery of highly potent pyrazole-based KDM5B inhibitor TK-129 (IC50 = 0.044 μM). TK-129 reduced Ang II-induced activation of cardiac fibroblasts in vitro, exhibited good PK profile (F = 42.37%), and reduced isoprenaline-induced myocardial remodeling and fibrosis in vivo. Mechanistically, we found that KDM5B up-regulation in cardiac fibroblast activation was associated with the activation of Wnt-related pathway. The protective effects of TK-129 were associated with its KDM5B inhibition and blocking KDM5B-related Wnt pathway activation. Taken together, TK-129 may represent a novel KDM5-targeting lead compound for cardiac remodeling and fibrosis.
30
Dickkopf-1 is a master regulator of joint remodeling
Danielle Diarra, Marina Stolina, Karin Polzer et al. · Nature Medicine · 2007 · 1.3K citations
Shigeki Iwase, Fei Lan, Peter Bayliss et al. · Cell · 2007 · 705 citations · Full text
An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells
Maia Vinogradova, Victor Gehling, Amy Gustafson et al. · Nature Chemical Biology · 2016 · 357 citations · Full text
Medicine, Oncology, Pharmacology +14